Patent Injunctions When Validity Is Challenged: Delhi High Court Clarifies the Legal Test in 2026

In early 2026, the Delhi High Court delivered a significant ruling on the interplay between interim injunctive relief in patent infringement proceedings and challenges to the validity of the patent in question. The ruling addresses a question that arises frequently in pharmaceutical, technology, and manufacturing patent disputes: when a patent holder seeks an interim injunction to restrain an alleged infringer, and the alleged infringer simultaneously challenges the validity of the patent, how should the court balance these competing claims? The Delhi High Court's approach provides important guidance for patent holders, generic manufacturers, and the broader intellectual property bar in India.

The Legal Framework for Patent Injunctions in India

Patent infringement actions in India are governed by the Patents Act, 1970, as amended by the Patents (Amendment) Acts of 2002 and 2005. When a patent holder believes that another party is manufacturing, selling, or importing a product that falls within the scope of its patent claims, it can file a suit for infringement and seek interim relief in the form of an injunction restraining the infringer from continuing the infringing activity during the pendency of the suit. The test for granting an interim injunction in India follows the well-established three-pronged framework: the plaintiff must demonstrate a prima facie case of infringement, the balance of convenience must favour the plaintiff, and the plaintiff must show that it would suffer irreparable harm if the injunction is not granted. However, patent cases introduce a complication that is not present in ordinary civil suits: the defendant can challenge the validity of the patent itself, either by way of a counterclaim in the infringement suit under Section 64 of the Patents Act or by filing a revocation petition before the Intellectual Property Appellate Board (now the High Court, following the abolition of the IPAB in 2021). When validity is challenged, the prima facie case assessment becomes significantly more complex.

The Delhi High Court's Approach

The Delhi High Court held that when a validity challenge is raised against a patent in an infringement proceeding, the court must conduct a more rigorous prima facie assessment than in a standard infringement case. Simply holding a granted patent is not sufficient to establish a prima facie case when the defendant has raised a credible challenge to the patent's validity on grounds such as lack of novelty, obviousness, or insufficient disclosure. The court must examine whether the validity challenge has a reasonable prospect of success at trial. If the validity challenge appears strong on a prima facie assessment, the court should be reluctant to grant an interim injunction because doing so would effectively enforce a patent that may ultimately be found invalid, causing unjustified harm to the defendant and potentially to public interest, particularly in cases involving pharmaceutical patents where access to affordable medicines is at stake. Conversely, if the validity challenge appears weak and the infringement case is strong, the court may grant interim relief to protect the patent holder's rights during the pendency of the suit. The key principle is that the grant of a patent creates a presumption of validity, but this presumption can be displaced at the prima facie stage if the defendant presents credible evidence of invalidity.

Pharmaceutical Patent Disputes and Public Interest

The ruling has particular significance for pharmaceutical patent disputes, which constitute a large proportion of patent litigation before the Delhi High Court. India's Patents Act incorporates specific provisions, most notably Section 3(d), that restrict the grant of patents for incremental innovations in pharmaceuticals, such as new forms, salts, polymorphs, or combinations of known substances, unless they demonstrate significantly enhanced efficacy. Generic manufacturers routinely challenge pharmaceutical patents on Section 3(d) grounds, arguing that the patent should not have been granted in the first place. When such challenges are raised in injunction applications, the court's willingness to conduct a rigorous validity assessment at the prima facie stage is critical. An overly lenient approach to injunctions would allow originator companies to delay generic entry for years while the suit is pending, effectively extending their market exclusivity beyond the patent term. The Delhi High Court's 2026 approach acknowledges this tension and requires courts to engage substantively with validity arguments before granting interim relief, rather than treating the grant of the patent as a conclusive indicator of its strength.

Practical Takeaways

Patent holders seeking interim injunctions should prepare for a rigorous prima facie hearing that goes beyond merely demonstrating ownership of a granted patent. Detailed claim construction, evidence of infringement, and a proactive response to anticipated validity challenges should be part of the injunction application from the outset. Generic manufacturers and alleged infringers should invest in building a strong validity challenge, supported by prior art evidence, expert opinions, and detailed technical arguments, as the strength of the validity defence will directly influence the court's decision on interim relief. The ruling applies not only to pharmaceutical patents but to all patent disputes before the Delhi High Court, including those involving technology, engineering, and consumer products. Legal practitioners should note that the Delhi High Court's Intellectual Property Division, which hears the bulk of India's patent litigation, now has a well-developed body of jurisprudence on this issue, and any departure from the principles articulated in this and earlier rulings is likely to be closely scrutinised on appeal. For companies investing in R&D and patent prosecution in India, the ruling underscores the importance of building a robust patent portfolio with claims that can withstand validity challenges, as the courts will not grant injunctive relief on the basis of weak or vulnerable patents.